Torasemide transport by organic anion transporters contributes to hyperuricemia

Journal of the American Society of Nephrology

Volumn 18, Issue 12, 2007, Pages 3101-3109

  Hagos, Yohannes ^a,b   Bahn, Andrew ^a   Vormfelde, Stefan V ^a   Brockmöller, Jürgen ^a   Burckhardt, Gerhard ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTER 4; TORASEMIDE; UNCLASSIFIED DRUG; URATE; URATE TRANSPORTER 1;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG ELIMINATION; DRUG TRANSPORT; EMBRYO; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPERURICEMIA; HYPOTHESIS; KIDNEY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; KIDNEY TUBULE EXCRETION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VOLUNTEER;

EID: 36849071941     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2007010106     Document Type: Article

References (24)

1. Brater DC: Benefits and risks of torasemide in congestive heart failure and essential hypertension. Drug Saf 14: 104-120, 1996
2. Neugebauer G, Besenfelder E, von Mollendorff E: Pharmacokinetics and metabolism of torasemide in man. Arzneimittelforschung 38: 164-166, 1988
3. Knauf H, Mutschier E: Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin Pharmacokinet 34: 1-24, 1998
4. Brater DC, Leinfelder J, Anderson SA: Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther 42: 187-192, 1987
5. Brater DC: Clinical pharmacology of loop diuretics. Drugs 41[Suppl 3]: 14-22, 1991
6. Barroso MB, Alonso RM, Jimenez RM: Simultaneous determination of torasemide and its major metabolite M5 in human urine by high-performance liquid chromatography-electrochemical detection. J Chromatogr Sci 39: 491-496, 2001
7. Wright SH, Dantzler WH: Molecular and cellular physiology of renal organic cation and anion transport. Physiol Rev 84: 987-1049, 2004
8. Sweet DH: Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol Appl Pharmacol 204: 198-215, 2005
9. Burckhardt BC, Burckhardt G: Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol 146: 95-158, 2003
10. Anzai N, Kanai Y, Endou H: Organic anion transporter family: Current knowledge. J Pharmacol Sci 100: 411-426, 2006
11. Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A: Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 18: 430-439, 2007
12. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Ho CS, Hosoyamada M, Takeda M, Sekine T, lgarashi T, Matsuo H, Kikuchi Y, Oda T, lchida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H: Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417: 447-452, 2002
13. Hediger MA, Johnson RJ, Miyazaki H, Endou H: Molecular physiology of urate transport. Physiology 20: 125-133, 2005
14. Reyes AJ: Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 17: 397-414, 2003
15. Hasannejad H, Takeda M, Taki K, Shin HJ, Babu E, Jutabha P, Khamdang S, Aleboyeh M, Onozato ML, Tojo A, Enomoto A, Anzai N, Narikawa S, Huang XL, Niwa T, Endou H: Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther 308: 1021-1029, 2004
16. Cha SH, Sekine T, Fukushima Jl, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59: 1277-1286, 2001
17. Vormfelde SV, Engelhardt S, Zirk A, Meineke I, Tuchen F, Kirchheiner J, Brockmoller J: CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin Pharmacol Ther 76: 557-566, 2004
18. Vormfelde SV, Schirmer M, Hagos Y, Toliat MR, Engelhardt S, Meineke I, Burckhardt G, Nurnberg P, Brockmoller J: Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin Pharmacol 62: 323-335, 2006
19. Miners JO, Rees DL, Valente L, Veronese ME, Birkett DJ: Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J Pharmacol Exp Ther 272: 1076-1081, 1995
20. Johnson RJ, Segal MS, Srinivas T, Ejaz A, Mu W, Roncal C, Sanchez-Lozada LG, Gersch M, Rodriguez-lturbe B, Kang DH, Acosta JH: Essential hypertension, progressive renal disease, and uric acid: A pathogenetic link? J Am Soc Nephrol 16: 1909-1919, 2005
21. Huang X: On global sequence alignment. Comput Appl Biosci 10: 227-235, 1994
22. Bakhiya N, Stephani M, Bahn A, Ugele B, Seidel A, Burckhardt G, Glatt H: Uptake of chemically reactive, DNA-damaging sulfuric acid esters into renal cells by human organic anion transporters. J Am Soc Nephrol 17: 1414-1421, 2006
23. Hagos Y, Burckhardt BC, Larsen A, Mathys C, Gronow T, Bahn A, Wolff NA, Burckhardt G, Steffgen J: Regulation of sodium-dicarboxylate cotransporter-3 from winter flounder kidney by protein kinase C. Am J Physiol Renal Physiol 286: F86-F93, 2004
24. Vormfelde SV, Sehrt D, Bolte D, Pahl S, Tzvetkov M, Brockmoller J: Hydrochlorothiazide efficacy and polymorphisms in ACE, ADD1 and GNB3 in healthy, male volunteers. Eur J Clin Pharmacol 1-7, 2006